RBR-59447vnActive, not recruitingPhase 2
Effects of the administration of AP1189, a pro resolutive pathways up regulator, on lung alterations of COVID-19 patients and impaired oxygenation
niversidade Federal de Minas Gerais0 sitesStarted: May 29, 2021Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Intervention
Eligibility Criteria
- Ages
- 18Y to 85Y (—)
Inclusion Criteria
- •Male and female subjects, 18 to 85 years of age hospitalized with COVID-19 infection; Written informed consent; Confirmed COVID-19 by the presence of SARS-CoV-2 nucleic acid by polimerase chain reaction; Pregnancy is excluded or unlikely (reliable contraception/post-menopausal women).
Exclusion Criteria
- •Progress to death is imminent and unavoidable in the opinion of the investigator; Participating in other clinical trials (except in COVID-19 antiviral drug trials); Any condition that in the view of the screening physician suggests that the patient is unable to comply with study procedures; Subjects treated with immunosuppressive drugs; HIV infection; Pregnant women or breastfeeding mothers; Estimated glomerular filtration rate less than 30ml/min; Severe liver disfunction (Child-Pugh score C); Medical history of oral glucocorticoid treatment (Exception is COVID-19 dexamethasone treatment not exceeding 10mg/day).
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Eficacia y seguridad de AP 12009 en pacientes adultos con astrocitoma anaplásico (grado III de la OMS) recurrente o refractario en comparación con el tratamiento estándar con Temozolomida o BCNU: Estudio clínico fase III aleatorizado, de control activo y etiqueta abierta.Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) as Compared to Standard Treatment with Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. - SAPPHIRERecurrent or Refractory Anaplastic AstrocytomaAstrocitoma anaplásico recurrente o refractarioMedDRA version: 9.1Level: LLTClassification code 10002224Term: Anaplastic astrocytomaEUCTR2007-005802-38-ESAntisense Pharma GmbH132
Completed
Not Applicable
Assessment of the effect of administration of propolis and curry leaf into periodontal pockets on oral microbiotaChronic periodontitisJPRN-UMIN000013850ational Institute of Infectious Diseases24
Active, not recruiting
Not Applicable
EFECTO DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA Y MIDODRINA ORAL SOBRE LA FUNCIÓN RENAL DE LOS PACIENTES CON CIRROSIS HEPÁTICA Y INSUFICIENCIA RENAL FUNCIONAL - MAFRIEUCTR2009-011437-27-ESFundació Clínic
Active, not recruiting
Phase 1
EFECTO DE LA ADMINISTRACIÓN PROLONGADA DE ALBÚMINA Y MIDODRINA EN LA PREVENCIÓN DE COMPLICACIONES EN PACIENTES EN LISTA DE ESPERA DE TRASPLANTE HEPÁTICOMidodrine and Albumin for CirrHotic patients in the waiting list for liverTransplantation - Midrodrine and albumin for cirrhotic patients in the waiting list for liver transplantatioPacientes afectos de cirrósis hepática en lista de espera para trasplante HepáticoMedDRA version: 9.1Level: LLTClassification code 10019641Term: Hepatic cirrhosisEUCTR2007-005723-14-ESFundació Clinic per a la recerca biomèdica
Active, not recruiting
Not Applicable
EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA SOBRE LA FUNCIÓN DIASTÓLICA DE LOS PACIENTES CON CIRROSIS HEPÁTICA.EUCTR2005-005083-81-ESHOSPITAL CLINIC